- Conditions
- Congenital Hyperinsulinism
- Interventions
- RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4
- Drug
- Lead sponsor
- Rezolute
- Other
- Eligibility
- 2 Years to 45 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1633–1656
of 8,447
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Disease, Diabetes, Obesity
- Interventions
- Social Cognitive Theory
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes
- Interventions
- lifestyle (exercise, diet, and family and community support)
- Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2004
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Abdominal Obesity
- Interventions
- Control, Resistance Exercise, Aerobic exercise
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 12 Years to 18 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2, Hyperglycemia
- Interventions
- Sitagliptin, Placebo
- Drug
- Lead sponsor
- Kathleen Dungan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- CARES Intervention
- Behavioral
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Pre-diabetes, Type II Diabetes, Insulin Resistance
- Interventions
- Not listed
- Lead sponsor
- PeriRx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hypoglycemia, Reactive, Hypoglycemia
- Interventions
- Dexcom CGM masked, Dexcom CGM unmasked
- Device
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stress, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Interventions
- Mindfulness Based Stress Reduction, Stress Management Education
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Gestational Diabetes
- Interventions
- Exenatide, Buccal/blood Sample Collection
- Drug · Genetic
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Diabetes
- Interventions
- Not listed
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- Not listed
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Temecula, California • Minneapolis, Minnesota • Portland, Oregon
- Conditions
- Type 2 Diabetes, Obesity & Overweight
- Interventions
- Nex Playground Activity Program
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 27
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
- Conditions
- Hypertriglyceridemia, Diabetes Mellitus
- Interventions
- Low Fat/High Carbohydrate, High Monounsaturated Fat/Low Carbohydrate
- Other
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Hyperkalemia
- Interventions
- Protein supplementation
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 1 Minute to 12 Hours
- Enrollment
- 62 participants
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetic Nephropathy
- Interventions
- Nidufexor, Placebo, Standard of Care (SoC)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 938 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
- Conditions
- Insulin Resistance, Oxidative Stress
- Interventions
- Alpha Lipoic Acid
- Dietary Supplement
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetes, Hyperglycemia
- Interventions
- 75 g glucose solution
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Lower Limb Amputation Below Knee, Diabetes (DM), Skin Temperature Change, Vascular Reactivity
- Interventions
- Warming stimulus starting at 30 C initial temperature, Warming stimulus starting at 32 C initial temperature, Warming stimulus starting at 34 C initial temperature, Warming stimulus starting at 35 C initial temperature, Cooling stimulus starting at 30 C initial temperature, Cooling stimulus starting at 32 C initial temperature, Cooling stimulus starting at 34 C initial temperature, Cooling stimulus starting at 35 C initial temperature
- Other
- Lead sponsor
- VA Puget Sound Health Care System
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PE0139 Injection, Placebo Injection
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Anniston, Alabama • Huntington Park, California • Bradenton, Florida + 3 more
- Conditions
- Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
- Interventions
- Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
- Procedure · Radiation · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Stanford, California